Fridgeirsson, Egill A.
Sontag, David
Rijnbeek, Peter
Funding for this research was provided by:
the Innovative Medicines Initiative 2 Joint Undertak (806968, 806968)
Article History
Received: 27 July 2023
Accepted: 27 November 2023
First Online: 7 December 2023
Declarations
:
: The current study was approved by IPCI Raad van Toezicht IRB and informed consent was waived by IPCI Raad van Toezicht institutional review board. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: DS was a consultant for and has equity in CureAI and ASAPP and has received compensation from speaking at Genentech. DS has a grant from Takeda. EF and PR work for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research & Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.